Skip to main content

Table 1 General characteristics of study participants1

From: The effects of vitamin D and omega-3 fatty acids co-supplementation on biomarkers of inflammation, oxidative stress and pregnancy outcomes in patients with gestational diabetes

  Placebo
(n = 30)
Vitamin D 2(n = 30) Omega-33
(n = 30)
Vitamin D+ omega-34
(n = 30)
P5
Age (y) 29.2 ± 3.4 29.9 ± 5.0 29.7 ± 3.6 29.9 ± 4.0 0.869
Height (cm) 161.6 ± 4.8 161.5 ± 4.1 161.5 ± 3.4 161.8 ± 3.7 0.985
Weight at study baseline (kg) 75.1 ± 7.7 76.1 ± 12.7 74.3 ± 5.8 77.4 ± 10.2 0.632
Weight at end-of-trial (kg) 77.5 ± 7.7 78.6 ± 12.5 76.7 ± 6.1 80.0 ± 10.0 0.559
Weight change (kg) 2.3 ± 0.7 2.5 ± 1.1 2.4 ± 0.5 2.6 ± 0.6 0.570
BMI at study baseline (kg/m2) 28.8 ± 3.4 29.2 ± 5.0 28.5 ± 2.4 29.5 ± 3.8 0.746
BMI at end-of-trial (kg/m2) 29.7 ± 3.4 30.1 ± 4.8 29.4 ± 2.5 30.5 ± 3.7 0.683
BMI change (kg/m2) 0.9 ± 0.3 1.0 ± 0.4 0.9 ± 0.2 1.0 ± 0.2 0.592
  1. 1Data are means ± SDs
  2. 2Receiving 50,000 IU vitamin D every 2 weeks plus placebo for omega-3 fatty acids twice a day
  3. 3Receiving 1000 mg omega-3 fatty acids (180 mg EPA and 120 mg DHA) twice a day plus placebo for vitamin D every 2 weeks
  4. 4Receiving 50,000 IU vitamin D every 2 weeks plus 1000 mg omega-3 fatty acids twice a day
  5. 5Obtained from ANOVA test